S0531 creates the “Patients’ Right to Transparency and Timely Access to Healthcare Services Act” and adds a new chapter to Title 44 governing prior authorization, step therapy, and related utilization review practices for South Carolina health benefit plans. The bill limits when health carriers may require prior authorization, including for certain preventive services, outpatient mental health treatment, outpatient substance use disorder treatment, and pain medication for terminally ill patients. It also creates a 90% approval-based exemption from prior authorization for providers, requires more transparent and clinically grounded review criteria, and sets short decision deadlines for urgent and nonurgent care.
The bill further protects patients with chronic conditions by making prior authorizations for ongoing treatment generally remain valid for the duration of treatment, and by preventing insurers from changing prescription drug coverage or cost-sharing mid-policy year except in limited circumstances. It requires step therapy protocols to be based on evidence-based clinical guidelines, provides a clear process for step therapy exceptions, and bars retroactive claim denials after prior authorization has been granted except in specified cases. It also requires continuity of prior authorization when a patient changes plans, mandates annual reporting of approval and denial data, and directs the Department of Insurance to enforce the chapter and adopt implementing regulations.
If enacted, the bill would significantly expand state regulation of health insurers, HMOs, pharmacy benefit managers, utilization review entities, and other health carriers operating in South Carolina. It would impose new disclosure, notice, reporting, and appeals obligations; restrict prior authorization for certain categories of care; require faster utilization review decisions; and limit insurers’ ability to change formulary placement or cost-sharing during a policy year. The bill also creates enforceable rights for covered persons, their representatives, and providers to file complaints with the Department of Insurance, while expressly excluding self-funded ERISA plans from most of its reach.
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate, amendments, or roll-call sentiment in the available record. Based on the bill text, the measure is framed in strongly patient-protective terms and appears designed to address frustration with delays, denials, and administrative burdens in health coverage. The overall tone is reform-oriented and consumer-focused, emphasizing transparency, continuity of care, and timely access to medically necessary treatment.
The main likely points of contention are the bill’s restrictions on insurer utilization management and the administrative and financial burden they may create for health carriers and pharmacy benefit managers. Insurers may object to the 90% exemption rule, the short turnaround times for decisions, the limits on retroactive denials, and the requirement to honor prior authorizations across plan changes and for chronic conditions. Providers and patient advocates are likely to support these provisions as reducing delays and treatment interruptions, while insurers may argue that the bill constrains cost control, medical management, and formulary flexibility.